Cremor hydrocortisoni PCH

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Cremor hydrocortisoni PCH

Quick Facts

Property Description
Active ingredient Hydrocortisone
Form Cream (Cremor)
Pharmacological class Corticosteroid (Glucocorticoid)
Common purpose Symptomatic relief of inflammation and itching
Origin Synthetic (Analogue of natural cortisol)

1. Defining Cremor hydrocortisoni PCH: Identity and Pharmacological Class

Cremor hydrocortisoni PCH is a distinct pharmaceutical product for topical application containing the active ingredient Hydrocortisone. This preparation is classified within the Pharmacological class of Corticosteroids, which are recognized for their anti-inflammatory properties. Hydrocortisone is a synthetic compound that mirrors cortisol, the steroid hormone naturally produced by the body, defining its function in regulating local inflammatory responses. The preparation is widely considered a low-potency topical steroid, a feature that distinguishes it as a first-line option for the management of mild, steroid-responsive conditions.

2. Composition and Pharmaceutical Form (Cremor)

The medicine is delivered in the Dosage form of a Cream, or Cremor, specifically designed for direct application onto the skin. The Cremor base, unlike highly occlusive ointments, is a water-washable emulsion, which aids in rapid absorption and is generally preferred for application to moist or exposed areas of the body. This particular formulation, featuring Hydrocortisone as the single monocomponent active substance, ensures that the therapeutic focus is solely on the steroid's anti-inflammatory properties. This characteristic cream base and low-potency agent is often used for managing common, localized skin irritations that require mild anti-inflammatory support.

3. General Therapeutic Intent and Action

The general purpose of this preparation is to provide effective, local symptomatic relief by modulating the body's inflammatory processes. Hydrocortisone achieves this through two key physiological actions: a strong anti-inflammatory effect and a significant anti-pruritic action. The mechanism of action works by activating natural substances in the skin to reduce swelling, redness, and itching. This means the cream's core benefit is quickly reducing signs, such as redness and swelling, and mitigating the uncomfortable sensation of itching.

Regulatory References

  1. Hydrocortisone Topical Information
Advertisements

What side effects are possible with Cremor hydrocortisoni PCH?

Possible side effects and safety information

The safety profile for topical hydrocortisone is primarily structured around application site reactions and the potential for systemic effects, as documented in official regulatory labeling.

Adverse Reaction Scope

Category Documented Effects/Characteristics
Key Organ Systems Skin and Subcutaneous Tissue Disorders, Endocrine Disorders, Eye Disorders.
Most Frequent Effects Burning, itching, irritation, and dryness at the application site.
Dermatological Changes Folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, skin atrophy (thinning), striae (stretch marks), and allergic contact dermatitis.
Not Known Frequency Blurred vision and signs of topical steroid withdrawal syndrome (TSWS) after cessation.

Serious Adverse Reactions and Safety Considerations

Systemic absorption, though typically low for this potency class, carries the documented risk of serious adverse reactions, which are more associated with long-term or extensive use. These include Hypothalamic-Pituitary-Adrenal (HPA) axis suppression and manifestations of Cushing's Syndrome. Ophthalmic complications, such as Cataracts and Glaucoma, are also listed as potential risks.

Population-Specific Safety: Pediatric patients are noted in official labeling to have a greater susceptibility to systemic effects due to their body surface area to mass ratio. Specific concerns documented for this group include growth retardation and delayed weight gain. For use during pregnancy, regulatory classification advises use only when the potential benefit outweighs the potential risk to the fetus, and extensive use is discouraged.

Safety Restrictions: Regulatory constraints prohibit the use of this cream in the presence of untreated bacterial, viral (e.g., herpes simplex), or fungal skin infections. Application is also specifically restricted for skin conditions such as rosacea and perioral dermatitis.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Hydrocortisone cream is generally safe when used as directed. Overdose from a single, excessive topical application is highly unlikely to cause immediate life-threatening issues due to the low absorption of the corticosteroid through the skin. However, using the cream too frequently, in excessive amounts, over large skin areas, on damaged skin, or under occlusive dressings for prolonged periods can lead to increased systemic absorption.

Potential Effects of Prolonged Overuse

Chronic, extensive overuse may result in systemic side effects, which are a concern because they mimic the effects of taking corticosteroid tablets. These effects include suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which is the body's natural system for regulating steroid production. Symptoms may include:

  • Cushing's syndrome-like features: Weight gain (especially in the face or upper body), easy bruising, and thinning of the skin.
  • Adrenal insufficiency: Fatigue, weakness, nausea, and vomiting, particularly when discontinuing the cream.
  • Local skin reactions: Severe skin thinning, stretch marks (striae), or an allergic-type rash.

When to Seek Medical Assistance

Seek immediate medical attention if you or someone else accidentally swallows the cream or in the event of any emergency. You should consult a doctor or pharmacist if you experience:

Situation Action to Take
Symptoms of systemic absorption (e.g., unexplained weight gain, extreme fatigue, vision changes) after prolonged use. Consult a doctor. Do not stop the cream abruptly without medical advice.
Signs of a severe skin reaction or infection (e.g., severe redness, pus, significant swelling, or a spreading rash). Consult a doctor immediately.
Signs of an allergic reaction (e.g., hives, difficulty breathing, swelling of the face, lips, tongue, or throat). Seek emergency medical care immediately.
The condition you are treating does not improve within seven days or worsens. Consult a doctor or pharmacist.
Advertisements

Therapeutic Uses of Cremor hydrocortisoni PCH

What Cremor hydrocortisoni PCH Treats: Main Uses and Benefits

Cremor hydrocortisoni PCH is applied across domains where additional symptomatic support is needed for conditions involving inflammatory or irritative processes. This topical preparation may be part of symptomatic management for various skin conditions. It is commonly used to help with symptoms related to redness, localized swelling, and intense itching (pruritus). The conditions it is relevant for easing include mild atopic dermatitis (eczema), contact dermatitis, localized psoriasis patches, and acute reactions like insect bites.

The primary purpose is to address the symptoms that interfere with daily comfort. By addressing these distressing manifestations, the cream supports patients during episodes of heightened discomfort. This low-potency agent is often relevant for managing mild, localized skin reactions occurring in thin or sensitive areas, assisting with managing symptoms that create noticeable functional strain.


Quick Fact: Relief for Inflammatory and Pruritic Symptoms

Feature Description
Core Benefit Symptomatic relief of inflammation and itching
Common Uses Eczema, dermatitis, mild psoriasis, insect bites
Symptom Targets Redness, localized swelling, and pruritus
Context Mild, localized, and episodic skin reactions
Benefit Focus Easing overall symptom load and improving comfort

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Cremor hydrocortisoni PCH?

This section defines population eligibility and non-eligibility strictly according to official regulatory documentation.

Absolute Non-Eligibility (Contraindications)

Use of Cremor hydrocortisoni PCH is contraindicated in patients with a known hypersensitivity to hydrocortisone or its excipients. The cream must not be applied to skin areas affected by untreated primary infections (bacterial, viral, fungal, or tuberculous). Absolute non-eligibility also applies to individuals with pre-existing skin conditions such as Rosacea, Acne vulgaris, Perioral dermatitis, or ulcers.

Age-Related Eligibility and Restrictions

The cream is generally approved for use in adults and older adults. Use in children under 2 years of age is generally not recommended due to an increased risk of systemic absorption and should only occur with specific medical direction. Use in all pediatric patients is restricted to short courses over limited body areas.

Conditional Use Categories

Eligibility is conditional for certain groups. For pregnant and nursing women, use is restricted and should only be undertaken if the potential benefit justifies the potential risk, avoiding extensive or prolonged application. Use is also restricted on the face, eyelids, and under occlusive dressings. Application is conditional for patients with conditions like psoriasis or systemic diabetes.

Advertisements

What should I know about interactions with other medicines?

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Potent inhibitors of the Cytochrome P450 3A4 (CYP3A4) enzyme.
Specific interacting medicines (if explicitly listed) Ritonavir and Cobicistat.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic inhibition of CYP3A4, resulting in potentially increased plasma concentrations of hydrocortisone.
Timing-based interaction rules (if applicable) None formally documented for the topical formulation.
Population-specific interaction notes (if applicable) Pediatric patients are noted for having greater systemic absorption due to an increased skin surface area-to-body mass ratio, leading to a potentially higher risk of interaction-related systemic effects.
Interaction-related restrictions Restriction is tied to the risk of systemic absorption, which is augmented by application to large surface areas, prolonged use, or use under occlusive dressings.
Food, alcohol, herbal product interactions None formally documented for the topical formulation under normal use.

Interaction Classifications (High-Level)

Category Official Regulatory Statement
Interaction severity classification (as defined in official documents) Classified as "Clinically Significant" only when systemic absorption is elevated.
Regulatory basis (EMA / FDA / etc.) Information is consistently presented across government drug authorities, including the FDA (DailyMed) and EMA-aligned national agencies.
Interaction-context constraints (as defined in official documents) The relevance of the interaction is strictly constrained by the degree of percutaneous absorption; in the absence of increased absorption, no known interactions are listed.

Resulting Interaction Structure

Official interaction statements:

  • No known interactions with other medicinal products are documented when the cream is used under normal conditions, due to minimal systemic absorption.
  • Co-administration with potent CYP3A4 inhibitors, such as ritonavir or cobicistat, has the potential to increase the systemic exposure of hydrocortisone if sufficient amounts are absorbed from the skin.
  • The risk of interaction-mediated systemic exposure is greater in pediatric patients due to their unique body surface area-to-mass ratio.

Connection to the overall interaction profile (3 sentences): Regulatory documents define the interaction profile of Cremor hydrocortisoni PCH by establishing that the lack of systemic exposure under normal use eliminates the risk of most common drug interactions. The primary interaction statement focuses on a pharmacokinetic risk: the potential for potent CYP3A4 inhibitors to increase systemic hydrocortisone levels if the skin barrier is compromised or if high-risk application methods are used. This makes the official interaction structure contingent upon the conditions of application and not on a routine, unavoidable interaction between co-administered drugs.

Advertisements

Mechanism of Action

Receptor Targeting and Gene Regulation

The active ingredient, hydrocortisone, functions as an agonist for the intracellular Glucocorticoid Receptor (GR). Upon cellular entry, the hydrocortisone-receptor complex translocates to the nucleus, where it binds to specific DNA sequences. This process is the core mechanistic step that modulates the transcription of genes, increasing the synthesis of anti-inflammatory proteins (e.g., Annexin A1) and diminishing the synthesis of pro-inflammatory mediators.

Blocking the Inflammatory Cascade

The mechanism of GR activation indirectly leads to the inhibition of key enzymes like phospholipase A2 (PLA2). Restricting PLA2 activity limits the cleavage of arachidonic acid from membrane phospholipids, thus reducing the available precursor for inflammatory eicosanoids such as prostaglandins and leukotrienes. This intervention modifies the sequence of events within the inflammatory cascade, reducing the potential for downstream mediator generation.

Modulation of Local Blood Vessel Response

The resulting shift in mediator production contributes to the final physiological effect: local vasoconstriction and decreased capillary permeability. These physiological changes restrict the movement of fluid and immune cells into the tissue, leading to a diminished vascular response.

Advertisements

Dosage and Administration Information

How to Use Cremor Hydrocortisoni PCH

The utilization of Cremor hydrocortisoni PCH is based on established regulatory principles for the application of topical corticosteroids, focusing on correct administration technique, frequency, and duration. This preparation is strictly intended for topical administration to the skin, and is for external use only.

Administration and Technique

Application involves placing a thin film of the cream onto the affected area, which should then be gently rubbed in until absorbed. Contact with the eyes and mucous membranes must be avoided during application. The area being treated should generally not be covered with an occlusive dressing, such as a bandage or plastic wrap, unless a specific instruction to do so has been provided by a healthcare professional.

Dosing and Treatment Duration

The frequency of application typically ranges from two to four times daily. This dosing is intended for the short-term management of inflammatory episodes. If a condition does not show improvement within seven days of use, the treatment course should be reassessed.

Use in Specific Populations

For the pediatric population, application should be limited to the minimum amount and frequency necessary to achieve the intended response. The total duration of treatment for children is often limited to a maximum of seven to ten days. When applied to the diaper area of infants, tight-fitting garments or plastic pants must not be used, as they act as an occlusive dressing and may increase systemic absorption.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Cremor hydrocortisoni PCH

Evidence for use in Atopic Dermatitis (Eczema) Studies

Research exploring this cream in studies for Atopic Dermatitis, or eczema, primarily involved Randomized Controlled Trials (RCTs) and numerous large-scale Systematic Reviews that synthesize the data from multiple clinical studies. These research scenarios focused on conditions characterized by fluctuating or episodic manifestations. Studies examined established severity scores and patient-reported outcomes describing perceived discomfort, particularly regarding pruritus (itching) and the visible signs of inflammation. Findings describe patterns observed in the studies related to key disease severity indicators. However, certainty remains low regarding outcomes beyond the defined study follow-up. The available evidence provides limited characterization of long-term outcomes or the effects of continued use.


Evidence for use in Contact Dermatitis and Localized Psoriasis

Research examined the use of this cream for allergic contact dermatitis through Randomized Controlled Trials (RCTs) and comparative studies. The primary endpoints were studied for patterns related to localized inflammatory states and the measurement of change in acute redness and swelling. For localized, mild psoriasis, research was studied for populations with lesions on thin-skinned or sensitive anatomical sites. Studies explored the measurement of physical features such as plaque thickness. However, comparative evidence is lacking, and most pivotal trials for psoriasis focus on higher-potency corticosteroids, leaving less primary trial data specifically for this low-potency agent.


Evidence in Special Populations and Duration of Follow-up

This cream was evaluated in studies involving both adults and children in the context of atopic dermatitis, as low-potency agents are studied for pediatric cohorts. Research also describes studies focused on thin-skinned or sensitive areas of the body, such as the face or skin folds. The typical follow-up durations in the core clinical trials have been limited, primarily to short-term outcome studies lasting only a few weeks. This limited duration contributes to the lack of information for long-term outcomes associated with chronic use, as long-term effects are not fully established in the current body of research.

Key Studies & References

  1. PUBLIC ASSESSMENT REPORT of the Medicines Evaluation Board in the Netherlands: Hydrocortison-vaselinecrème 1% FNA, cream 10 mg/g (Source for regulatory context and indications)
  2. Clinical Practice Guidelines: Eczema - The Royal Children's Hospital (Source for low-potency use in sensitive areas/children)
  3. Hydrocortisone Cream USP, 2.5% and Hydrocortisone Ointment USP, 2.5% - DailyMed (FDA Labeling/Indications context)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Cremor hydrocortisoni PCH (FAQ)


Q: Is it okay to use Cremor hydrocortisoni PCH on my face?

Official regulatory documents describe that topical hydrocortisone is restricted from use on the face unless specifically directed by a healthcare professional. This restriction is due to the face's thinner, more sensitive skin, which carries a higher potential for systemic absorption and local side effects. Regulatory constraints require limited treatment duration in this area.


Q: Can I use other medicated creams or ointments at the same time as this one?

Official guidance describes a requirement to avoid applying other topical products, including medicated creams, at the same time as the hydrocortisone cream. A time separation, such as waiting at least 30 minutes between applications, is generally referenced. This practice is intended to prevent the active medicine from being diluted, which could potentially reduce its effectiveness.


Q: Can I use this cream on sensitive skin areas?

Use on sensitive or thin-skinned areas, such as skin folds, the eyelids, or genital skin, is described in official information as typically restricted. These areas are more susceptible to side effects like skin thinning (atrophy) due to increased absorption. Therefore, application to such sites is subject to strict limitations regarding duration and frequency, requiring medical oversight.


Q: Can I use Cremor hydrocortisoni PCH for diaper rash on a baby?

While low-potency hydrocortisone is indicated for certain inflammatory conditions in the diaper area, regulatory documents include a specific precaution. When the cream is applied to infants, the treated area must not be covered with tight-fitting diapers or plastic pants. These materials function as occlusive dressings, substantially increasing the risk of systemic absorption of the medicine.


Q: Is there a rebound effect if Cremor hydrocortisoni PCH is stopped suddenly?

Official documents note that a collection of symptoms referred to as Topical Steroid Withdrawal Syndrome (TSWS) may occur after ceasing prolonged or frequent use of the medicine. These reactions can include a temporary return or worsening of the original skin condition, which is sometimes described by users as a rebound effect. This phenomenon is a documented safety consideration.


Q: Why is it advised to avoid using this cream near the eyes?

Official labeling includes a specific safety instruction to avoid contact with the eye area. This precaution exists because the use of topical corticosteroids near the eyes is associated with a potential risk of developing serious ophthalmic complications. These complications, which are rare, include cataracts and glaucoma.


Q: What is the typical expectation for symptom relief after starting treatment?

Official product information indicates that an improvement in the condition is generally expected within seven days of starting treatment. If no visible improvement is observed after this period, regulatory instruction suggests that the use of the medicine should be discontinued and the treatment course should be professionally reassessed.


Q: Are there specific ingredients in the cream base that help with absorption?

The extent of the medicine's percutaneous absorption is known to be significantly influenced by the formulation's vehicle, or cream base, and its specific components. Regulatory texts confirm that the cream base itself, being a water-washable emulsion, generally aids in the rapid delivery of the active ingredient to the skin.


Q: Is this cream available over the counter or is a prescription required?

The regulatory status of topical hydrocortisone is dependent on its strength. Lower-potency concentrations, such as the 0.5% or 1% formulations, are typically available for purchase without a prescription (over the counter). Higher concentrations, such as 2.5% cream, generally require a medical prescription.


Q: Does sun exposure affect the use of Cremor hydrocortisoni PCH?

Topical hydrocortisone does not provide any sun protection factor (SPF) and is not formally indicated for application immediately prior to sun exposure. Official guidance states that increased sensitivity to sunlight has been reported as a potential factor in some skin reactions associated with topical steroid use.


Q: Are there different strengths of hydrocortisoni PCH cream?

Yes. Official regulatory documents indicate that hydrocortisone topical creams are broadly available in different strengths. These commonly include 0.5%, 1%, and 2.5% formulations. The specific strength prescribed or purchased dictates its potency classification.


Q: What happens if I forget to use the cream at the usual time?

Official regulatory instruction emphasizes using the medication exactly as directed to maintain consistent treatment. Standard guidance for a missed application indicates that the cream should be applied as soon as it is remembered, and then the patient should return to their regular schedule.


Q: Does using moisturizer affect how Cremor hydrocortisoni PCH works?

Official guidance confirms that applying moisturizers (emollients) at the same time as the cream may affect its action. Applying emollients immediately beforehand can dilute the medication and potentially reduce its effectiveness. For this reason, official practice describes a waiting period of at least 30 minutes between the application of the two products.


Q: Does the cream contain ingredients like alcohol, lanolin, or preservatives?

Yes. Official drug labels list all inactive ingredients (excipients) contained in the formulation. These often include specific preservatives (such as parabens), alcohol components (like cetyl or stearyl alcohol), and lanolin or lanolin-related compounds. The full list of excipients is available for review in the 'Inactive Ingredients' section of the product label.


Q: Is Cremor hydrocortisoni PCH effective for insect bites or stings?

Studies and regulatory indications support the use of hydrocortisone for the symptomatic relief of inflammation and itching in corticosteroid-responsive skin conditions. Furthermore, certain official package leaflets specifically list inflammatory reactions from insect bites as an approved use for this type of cream.


Q: Can I apply makeup or sunscreen over the area treated with the cream?

Official guidance suggests that the cream should be allowed to fully absorb before applying any subsequent topical products, including cosmetics like makeup or sunscreens. A waiting period helps ensure the medicine is not diluted. The cream itself does not provide sun protection.


Q: What should be done if too much cream is accidentally applied?

Regulatory guidance states that if excessive amounts of the cream are used on an occasional basis, it is generally not a concern. However, routine overuse of more than the recommended amount carries a heightened risk of potential systemic side effects.


Q: What research is available on using this cream for anal itching (pruritus ani)?

Hydrocortisone is indicated for the relief of pruritus (itching) associated with corticosteroid-responsive dermatoses. For anal itching (pruritus ani), specific rectal forms of hydrocortisone are formally approved for this condition, reflecting its use as an anti-pruritic agent.

Advertisements

How should Cremor hydrocortisoni PCH be stored and disposed of?

How to Store and Dispose of Cremor hydrocortisoni PCH?

Official regulatory documents define strict requirements for storing and disposing of this medicine to ensure product stability and safety.


Storage Conditions

Hydrocortisone Cream must be stored below 25 C or 30 C, depending on the specific formulation. The product requires protection from light and moisture and the container must be kept tightly closed when not in use. A mandatory safety instruction requires the medicine to be kept out of the sight and reach of children.


Disposal Instructions

Any unused or expired Cremor hydrocortisoni PCH, along with waste materials, must be disposed of in accordance with local requirements. This instruction prevents inappropriate disposal through household trash or wastewater systems, ensuring adherence to environmental and pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cremor hydrocortisoni PCH found in:

A-Z Index: